National University Hospital

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

Retrieved on: 
Monday, March 4, 2024

Osteoarthritis of the knee is a debilitating disease affecting Singapore’s aging population and the clinical trial will pioneer stem cell use for regenerative medicine in Singapore.

Key Points: 
  • Osteoarthritis of the knee is a debilitating disease affecting Singapore’s aging population and the clinical trial will pioneer stem cell use for regenerative medicine in Singapore.
  • UC-MSCs are a type of adult stem cells that can be isolated from the umbilical cord tissue after childbirth.
  • UC-MSCs are considered multipotent and are able to differentiate into different cell types, including bone, cartilage, fat, and muscle cells.
  • "Our collaboration with CytoMed marks a significant step in advancing research on allogeneic in-vivo UC-MSC for cartilage repair, including osteoarthritis of the knee.

AI Medical Service Inc. Completes First Regulatory Review and Device Registration of Gastric AI-based Endoscopic Diagnosis Support System from Singapore’s HSA

Retrieved on: 
Tuesday, February 20, 2024

AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce the first instance of Singaporean regulatory review and device registration for an AI-based endoscopic diagnostic support device that operates within the stomach (brand name: Endoscopic image diagnosis support software - gastroAI-model G).

Key Points: 
  • AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce the first instance of Singaporean regulatory review and device registration for an AI-based endoscopic diagnostic support device that operates within the stomach (brand name: Endoscopic image diagnosis support software - gastroAI-model G).
  • The regulatory review and device registration was conducted by Singapore’s Health Sciences Authority (hereinafter HSA) on February 19, 2024.
  • The endoscopic AI (hereinafter gastric cancer differentiation AI) differentiates gastric lesions and judges them as either neoplastic or non-neoplastic in nature.
  • In countries with a high incidence of gastric cancer like Japan and South Korea, endoscopic gastric cancer screening is routinely performed nationwide.

Wonder Tech's Breakthrough in Language Agnostic Voice AI to Bring Scalable Depression Screening to One Billion People Globally

Retrieved on: 
Tuesday, November 28, 2023

LTD ("Wonder Tech" or "the Company"), a leading AI-driven mental health solutions company based in Singapore, has reached a breakthrough in its acoustics-based AI for depression screening.

Key Points: 
  • LTD ("Wonder Tech" or "the Company"), a leading AI-driven mental health solutions company based in Singapore, has reached a breakthrough in its acoustics-based AI for depression screening.
  • The AI model, which identifies depression through detecting nuanced vocal changes, has reached an industry-leading 83% in detection accuracy, surpassing the 80% threshold required for clinical depression detection.
  • With this milestone, Wonder Tech has proven its potential to enable a scalable and adaptable diagnostic tool to help the one billion people affected by mental health disorders worldwide.
  • Wonder Tech also received financial and clinical support from Singapore's Ministry of Health to scale out the solution with leading mental health institutes.

NATIONAL UNIVERSITY HOSPITAL LAUNCHES GLOBAL FELLOWS ALLIANCE TO FOSTER INTERNATIONAL HEALTHCARE COLLABORATION

Retrieved on: 
Thursday, October 19, 2023

SINGAPORE, Oct. 19, 2023 /PRNewswire/ -- In line with its mission of being Singapore's leading university hospital, the National University Hospital (NUH) is launching its highly anticipated Global Fellows Alliance. This is a pioneering initiative that aims to open doors for clinicians to engage with one another, collaborate on innovative healthcare solutions, and contribute to the advancement of medical knowledge in the region and beyond.

Key Points: 
  • SINGAPORE, Oct. 19, 2023 /PRNewswire/ -- In line with its mission of being Singapore's leading university hospital, the National University Hospital (NUH) is launching its highly anticipated Global Fellows Alliance.
  • On 19 October, more than 50 of these fellows are gathering back in Singapore for the official launch of the Global Fellows Alliance.
  • The Global Fellows Alliance will offer a unique blend of educational activities, professional development and networking opportunities.
  • Professor Quek Swee Chye, Chairman of the Medical Board at NUH, said: "Healthcare knows no borders and the Global Fellows Alliance is a testament to our shared commitment to strengthening healthcare excellence on a global scale.

SINGAPORE AND JAPAN CLINICIAN-SCIENTISTS COLLABORATE ON GROUNDBREAKING TELESURGERY TRIAL SPANNING OVER 5,000KM

Retrieved on: 
Wednesday, October 11, 2023

SINGAPORE, Oct. 11, 2023 /PRNewswire/ -- Singapore's National University Hospital (NUH) and the Yong Loo Lin School of Medicine at the National University of Singapore (NUS Medicine) are collaborating with Fujita Health University (FHU) in its first robotic telesurgery trial between Singapore and Japan, from 9 to 11 October 2023.

Key Points: 
  • Leveraging Japan's first surgical robot, clinician-scientists from NUH and NUS Medicine will remotely perform a gastrectomy (stomach surgery performed for cancer) from a surgeon cockpit in Singapore.
  • This collaboration follows the Memorandum of Understanding (MOU) signed in August 2023 between NUS Medicine and FHU, one of Japan's leading universities with a strong research focus in robotic surgery and telesurgery.
  • In Japan, the surgical team is led by Professor Ichiro Uyama and Professor Koichi Suda from Fujita Health University.
  • During public health crises, such as a global pandemic, remote telesurgery helps minimise the risk of disease transmission between patients, healthcare workers, and surgical teams.

Nature-inspired pressure sensing technology aims to transform healthcare and surgical robots

Retrieved on: 
Friday, August 18, 2023

SINGAPORE, Aug. 18, 2023 /PRNewswire/ -- Researchers at the National University of Singapore (NUS) have developed a novel aero-elastic pressure sensor, called 'eAir'. This technology can be applied to minimally-invasive surgeries and implantable sensors by directly addressing the challenges associated with existing pressure sensors.

Key Points: 
  • This technology can be applied to minimally-invasive surgeries and implantable sensors by directly addressing the challenges associated with existing pressure sensors.
  • It can potentially transform laparoscopic surgeries by enabling tactile feedback for surgeons, allowing more precise manipulation of patient tissues.
  • Mimicking this effect, the team has engineered a pressure sensor designed to significantly improve the sensing performance.
  • At the same time, they have filed a patent for the eAir sensor technology in Singapore, and aims to translate the technology for real-world applications.

Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

Retrieved on: 
Tuesday, August 1, 2023

SINGAPORE, Aug. 1, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced that the chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology, which is exclusively licensed from the Agency for Science, Technology and Research (A*STAR), has been granted a patent by the China National Intellectual Property Administration (CNIPA).

Key Points: 
  • The Company holds an exclusive, worldwide license, for use in immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
  • CytoMed's CAR-γδ T cell technology has been developed as an investigational cancer therapy to target NKG2D ligands, a type of stress-induced cancer antigens.
  • The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive a novel synthetic γδ NKT cells for the treatment of various types of cancers.
  • A patent for this proprietary technology has already been granted in Japan, and this asset is under preclinical development.

A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US

Retrieved on: 
Thursday, July 6, 2023

Our CAR-γδ T cell technology has received a US patent as we embark on our first-in-human trial.

Key Points: 
  • Our CAR-γδ T cell technology has received a US patent as we embark on our first-in-human trial.
  • CytoMed holds an exclusive, worldwide license, for use on immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
  • The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive γδ NKT cells for cancer treatments.
  • A patent for this proprietary technology has already been granted in Japan and this asset is under preclinical development.

LifeStrands Genomics and Ambry Genetics to Provide Laboratory Testing for Clinical Implementation Pilots in Phase II of Singapore’s National Precision Medicine Programme

Retrieved on: 
Wednesday, April 19, 2023

LifeStrands Genomics and Ambry Genetics have joined forces to provide clinical genetic testing services in Singapore.

Key Points: 
  • LifeStrands Genomics and Ambry Genetics have joined forces to provide clinical genetic testing services in Singapore.
  • Together, they have been chosen to support the Clinical Implementation Pilots (CIPs) for Phase II of Singapore’s National Precision Medicine (NPM) programme through an open tender commissioned by Precision Health Research, Singapore (PRECISE) – the central entity implementing NPM.
  • As part of the agreement, LifeStrands will provide the testing menu from Ambry Genetics and sequence the samples in its accredited laboratory, while Ambry Genetics will provide data interpretation and reporting.
  • We are delighted that LifeStrands Genomics has partnered with Ambry Genetics to offer these tests in Singapore,” said Professor Tai E Shyong, Chief Medical Officer, PRECISE.

AIRS Medical showcases award-winning MRI enhancement AI solution at RSNA 2022

Retrieved on: 
Monday, November 14, 2022

SEOUL, South Korea, Nov. 14, 2022 /PRNewswire/ -- AIRS Medical, Inc., a leading medical AI solution provider, announced its participation in the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA 2022), the world's leading annual imaging forum at McCormick Place inChicago held from November 27 to 30th.

Key Points: 
  • SEOUL, South Korea, Nov. 14, 2022 /PRNewswire/ -- AIRS Medical, Inc., a leading medical AI solution provider, announced its participation in the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA 2022), the world's leading annual imaging forum at McCormick Place inChicago held from November 27 to 30th.
  • At RSNA booth #4744 , AIRS Medical showcases SwiftMR, an FDA 510(k)-cleared AI Imaging solution that enhances MR images acquired under various conditions, contributing to better image quality and patient experience.
  • AIRS Medical Inc., founded inOct 2018, is a medical AI company based inSeoul, Korea, that develops innovative products and services to improve patient experience.
  • AIRS Medical helps healthcare systems achieve greater institutional efficiency in areas where a lack of productivity limits clinical value.